Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts. On July 25, Sanofi (NASDAQ:SNY) ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease.